VIR (Vir Biotechnology) Other Long-Term Liabilities: $53.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIR Vir Biotechnology Inc VIR
52 GF Score
Price $9.77
GF Value $42.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Vir Biotechnology Other Long-Term Liabilities?

Vir Biotechnology VIR +2.84% 52 Other Long-Term Liabilities is $53.2 Mil as of Jun. 2026. GuruFocus rates VIR with a GF Score™ of 52/100 and a GF Value™ of $42.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Vir Biotechnology's other long-term liabilities for the quarter that ended in Jun. 2026 was $53.2 Mil.

Vir Biotechnology's quarterly other long-term liabilities declined from Dec. 2025 ($55.7 Mil) to Mar. 2026 ($52.6 Mil) but then increased from Mar. 2026 ($52.6 Mil) to Jun. 2026 ($53.2 Mil).

Vir Biotechnology's annual other long-term liabilities declined from Dec. 2023 ($41.7 Mil) to Dec. 2024 ($38.6 Mil) but then increased from Dec. 2024 ($38.6 Mil) to Dec. 2025 ($55.7 Mil).

Vir Biotechnology Other Long-Term Liabilities Related Terms

Vir Biotechnology Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Vir Biotechnology's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vir Biotechnology Other Long-Term Liabilities Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 25.36 36.05 41.74 38.63 55.68

Vir Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.65 47.49 55.68 52.63 53.22
VIR
52GF Score
Vir Biotechnology Inc VIR
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vir Biotechnology Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $53.2 Mil mean?
Vir Biotechnology (VIR) has a Other Long-Term Liabilities of $53.2 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vir Biotechnology and its competitors.
Is Vir Biotechnology's Other Long-Term Liabilities too high?
Vir Biotechnology's current Other Long-Term Liabilities is $53.2 Mil. Overall, Vir Biotechnology has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Other Long-Term Liabilities compare to AVBP and XNCR?
Vir Biotechnology's Other Long-Term Liabilities of $53.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current Other Long-Term Liabilities is $53.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $42.20, compared to a current price of $9.77 — trading 76.8% below its estimated fair value. The current Other Long-Term Liabilities is $53.2 Mil. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current Other Long-Term Liabilities is $53.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vir Biotechnology (VIR) Overvalued in 2026?

Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued. The current stock price of $9.77 is trading 76.8% below its estimated GF Value™ of $42.20. GuruFocus considers Vir Biotechnology to be Possible Value Trap.

Key valuation signals for VIR:

  • Other Long-Term Liabilities: $53.2 Mil
  • GF Value™: $42.20 vs. price of $9.77 (76.8% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vir Biotechnology Business Description

Address 1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score

Get the complete analysis for VIR

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.77
Price
$42.20
GF Value